Cardinal HealthCAH
Recorded

Cardinal Health 2027 Q1 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ1 2027Duration49 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone. Thank you for joining us, and welcome to Cardinal Health Incorporated First Quarter Fiscal Year 2027 Earnings Release. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to David Frost, Vice President, Investor Relations. David, please go ahead. Good morning.

David FrostVP of Investor Relations

Welcome to Cardinal Health's First Quarter Fiscal 2027 Earnings Conference Call, and thank you for joining us. With me today are Cardinal Health CEO, Jason Hollar, and our CFO, Aaron Alt. You can find this morning's earnings press release and investor presentation on the Investor Relations section of our website at ir.cardinalhealth.com. Since we will be making forward-looking statements today, let me remind you that the matters addressed in these statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statements slide at the beginning of our presentation for a description of these risks and uncertainties. Please note that during our discussion today, the comments will be on a non-GAAP basis unless specifically called out as GAAP.

David FrostVP of Investor Relations

GAAP to non-GAAP reconciliations for all relevant periods can be found in the supporting schedules attached to our press release. For the Q&A portion of today's call, we kindly ask that you limit questions to one per participant so that we can try and give everyone an opportunity. With that, I will now turn the call over to Jason.

Jason HollarCEO

Good morning, and thank you for joining us. I am pleased to report a strong start to fiscal 2027, with broad-based growth once again across the enterprise. This quarter's results reflect disciplined execution and continued progress against our strategic priorities. We are strengthening our core while investing in the capabilities that will drive growth and long-term value creation. As election results have come into focus, our priorities remain consistent. We have a longstanding record of constructive engagement with policymakers on both sides of the aisle. Our focus on better access, lower cost, and continued innovation aligns with objectives shared across the political spectrum. Any policy changes will take time, and we would expect to be manageable as we continue to be active in our engagement with government.

Jason HollarCEO

Our essential role across the healthcare ecosystem positions us to contribute meaningfully to those conversations, and in the meantime, our teams remain focused on delivering for customers and patients every day. Performance demonstrates the value of Cardinal Health's scale, reach, and capabilities across the healthcare ecosystem. Recently, we announced the renewal of our largest customer, CVS Health, through June 2032. This reflects our longstanding relationship, which predates CVS Health's acquisition of Aetna. The renewal reinforces the strategic value and stability that the partnership with Cardinal Health brings to CVS's retail pharmacy network, something that will continue beyond the spin-off in 2028. Just as importantly, when combined with our other recent significant renewals, it provides a steady foundation for continued investment in the business and supports the sustained execution of our growth strategies.

Jason HollarCEO

In Global Medical Products and Distribution, performance was stable, notwithstanding global volatility as the team continued to execute the GMPD Improvement Plan, including actions to optimize the network, improve efficiency, and grow Cardinal Health brand. We remain encouraged by our progress while recognizing there's more opportunity ahead to continue to optimize this segment. Our other growth businesses also delivered positive results, supported by healthy demand from underlying secular trends, the investments we've made to build differentiated positions, and a firm focus on integrating the acquisitions in at-Home. Taken together, the quarter's performance and our visibility into the balance of the year give us confidence to raise our fiscal 2027 outlook, which Aaron will walk through in more detail. With that, I'll turn the call over to Aaron.

Aaron AltCFO

Good morning. The Cardinal Health team delivered a strong first quarter above and below the line on the income statement and with respect to cash flow. Our performance was characterized by strong demand across the enterprise, led by our Pharmaceutical and Specialty Solutions segment and our other operating businesses. Demand was matched by good operational execution by all of our teams. Given our Q1 delivery, we are pleased to raise our fiscal 2027 EPS guidance to $12.80 to $13 from the previous range of $12.40 to $12.60. Moving on to our consolidated first quarter results, total company revenue grew 5% to $67.5 billion. Consolidated gross profit increased 12% to $2.6 billion.

Aaron AltCFO

We saw continued strength in our core distribution operations, expanded contributions from our investments in specialty, and gross profit increases from our three growth businesses and other. Consolidated SG&A grew more slowly, increasing 9% to $1.6 billion. In addition to servicing growing sales, we continue to invest in capabilities for our businesses while also remaining focused on simplification and cost optimization. As gross profit grew faster than SG&A, our operating income grew 17% to $1 billion, achieving that milestone in a quarter for the first time and highlighting the operating leverage we are pursuing. Moving below the operating line, interest and other was $67 million, and our effective tax rate for the first quarter was 18.5%. We are pleased with our progress and continue to focus on building durable improvements to items below the line.

Aaron AltCFO

After completing a $500 million accelerated share repurchase program during the quarter, our diluted weighted average shares outstanding for the quarter were approximately 233 million shares. All in, our efforts resulted in first quarter diluted earnings per share growth of 28%, or $3.26. Let's turn to the specific segment results, beginning with Pharma. Segment revenue increased 6% to $62.6 billion, driven by growing brand and specialty sales from existing customers. Specialty grew at an 18% clip during the quarter. While the business put up 6% revenue growth in the quarter, we again observed offsetting top-line revenue growth dynamics. GLP-1 medications, which continue to grow on pace, drove approximately 500 basis points of revenue growth in the quarter. That was offset in large part by the impact of IRA WAC reductions, which drove a 400 basis point revenue headwind year-over-year.

Aaron AltCFO

Segment profit in Pharma increased 17% to $783 million. This robust performance reflects healthy contributions from brand, specialty, and our generics program, where we continue to observe consistent market dynamics. The core distribution business remains highly resilient, and our strategic sourcing initiatives, notably our Red Oak Sourcing partnership, continue to drive significant value. Pharma segment profit also reflected the contribution of our Solaris acquisition, which we will lap in the second quarter. MSOs are a part of our broader specialty strategy, and we remain focused on integration and building the capabilities needed for long-term growth. Now, moving to our Global Medical Products and Distribution segment. Segment revenue was roughly flat to prior year at $3.2 billion. This top-line result was driven by growth in Cardinal Health brand, offset by lower distribution revenue during the period.

Aaron AltCFO

Segment profit for GMPD was higher than expected at $33 million for the quarter. We saw steady improvement in underlying operational performance as our team continued to execute against our GMPD Improvement Plan. We continue to see healthy demand for our Cardinal Health brand products, with U.S. growth in the low to middle single digits for the quarter. Foreign exchange and distribution were headwinds, while on the cost side, modest commodity pressure, primarily in transportation costs, was offset by tariff tailwinds. Now let's turn to other, which encompasses our three growth businesses. As we have remarked in the past, these businesses operate in markets aligned with powerful secular trends, including the aging population, the shift to home-based care, and complex medical innovation, and our results continue to reflect these favorable trends. Revenue for other grew 7% to $1.8 billion, and profit increased 16% to $193 million.

Aaron AltCFO

With profit growing well above our long-term targets and at more than twice the rate of revenue, our results in Q1 demonstrate our smart growth strategy in action. All three businesses and other delivered revenue and profit growth as we continue to invest in each business's distinct priorities. Turning to cash and the balance sheet, we ended the first quarter with $5.3 billion of cash after generating $1.6 billion of adjusted free cash flow. We took several actions aligned to our capital allocation framework, including investing $157 million of capital into our business, executing the $500 million share repurchase program I referenced earlier, and returning approximately $125 million to shareholders through dividends. We finished the quarter near the midpoint of our targeted leverage range and preserved our strong investment grade ratings. Let's talk about our fiscal 2027 guidance.

Aaron AltCFO

We are raising our non-GAAP diluted EPS guidance to a new range of $12.80-$13.00, up from our prior range of $12.40-$12.60. This updated guidance represents 17%-19% growth off our ex-tariff refund adjusted fiscal 2026 EPS of $10.95, and 14%-15% growth off our reported fiscal 2026 EPS of $11.26. This raise reflects the broad-based operating momentum we see across the business and our confidence in continuing to deliver robust profit growth across our operating segments. For the pharma segment, while we continue to expect revenue growth of 3%-5%, consistent with our original guidance, we have increased our segment profit growth guidance to a range of 10%-12% from the prior guidance of 8%-11%.

Aaron AltCFO

For those wondering about our recent renewals, our original profit guidance for fiscal 2027 largely anticipated the financial impact of the CVS renewal. Recall that we provided guidance on the basis of a consistent book of business. Our updated guidance also assumes continued strong demand and performance across our core distribution, generic sourcing, and specialty business. For modeling purposes, following strong growth in the first quarter, we expect earnings growth to moderate in the second and third quarters before strengthening in the fourth quarter to a level modestly below Q1. This is largely a result of the timing of the year-over-year impact of customer renewals and lapping the Solaris acquisition. For the Global Medical Products and Distribution segment, we continue to expect revenue growth of 2%-4%.

Aaron AltCFO

While we are not changing our financial guidance for GMPD for the year, we do note that sustained high petroleum costs driven by the ongoing Iran conflict are pushing GMPD's segment profit toward the low end of our guidance range of $200 million-$220 million. We remain highly focused on driving long-term profitability through our operational improvements plan in GMPD and expect the segment's results to be weighted towards the back half of the fiscal year, consistent with historical trends. For modeling purposes, we expect the second quarter to be generally consistent with the Q1 result, with sequential quarterly growth for the remainder of the year thereafter. For other, we anticipate revenue growth of 12%-14%, up from our previous range of 11%-13%, driven by strong demand across all three operating businesses.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day